SCHEMBL4469241

SCHEMBL4469241

Cc1[nH]c(C)c(-c2ccc(Oc3cccc(C(F)(F)F)c3)cc2)c(=O)c1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.51
TLR8 Q9NR97 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
KIF11 P52732 1/20 0.43
CHEK2 O96017 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SCN9A Q15858 1/20 0.40
LTA4H P09960 1/20 0.38
BRD4 O60885 1/20 0.38
PPARG P37231 3/20 0.37
NR3C1 P04150 1/20 0.37
PGR P06401 1/20 0.37
AR P10275 1/20 0.37
ESR2 Q92731 1/20 0.37
NPBWR1 P48145 1/20 0.36
MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560834 0.88 SLC2A1 (0.44) SLC2A1TLR8TLR7KIF11CHEK2
SCHEMBL9268964 0.88 SLC2A1 (0.58) SLC2A1KIF11CHEK2NPBWR1MCHR1
SCHEMBL13439218 0.87 TLR8 (0.42) SLC2A1TLR8TLR7KIF11CHEK2
SCHEMBL9266167 0.86 SLC2A1 (0.51) SLC2A1SCN9A
SCHEMBL9268107 0.86 SLC2A1 (0.57) SLC2A1TLR8TLR7KIF11CHEK2
SCHEMBL4472453 0.81 SLC2A1 (0.58) SLC2A1KIF11SCN9ANPBWR1MCHR1
SCHEMBL19047179 0.80 BRD4 (0.45) SLC2A1KIF11CHEK2KDM4EALDH1A1
SCHEMBL9270359 0.79 SLC2A1 (0.78) SLC2A1CHEK2MAPTLMNANPSR1
SCHEMBL3562873 0.77 CHEK2 (0.43) SLC2A1TLR8TLR7KIF11CHEK2
SCHEMBL4492018 0.76 SLC2A1 (0.51) SLC2A1KDM4EALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
US-5403934-A Heterocyclic compounds BURROUGHS WELLCOME CO. (US) 1995-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885TLR8 2583/4885TLR7 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.